Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec 7;7(1):21.
doi: 10.1186/1710-1492-7-21.

Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma

David I Bernstein  1 , Jacques Hébert, Amarjit Cheema, Kevin R Murphy, Ivan Chérrez-Ojeda, Carlos Eduardo Matiz-Bueno, Wen-Ling Kuo, Hendrik Nolte
Affiliations

Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma

David I Bernstein et al. Allergy Asthma Clin Immunol. .

Abstract

Background: Mometasone furoate/formoterol (MF/F) is a novel combination therapy for treatment of persistent asthma. This noninferiority trial compared the effects of MF/F and fluticasone propionate/salmeterol (FP/S) combination therapies on pulmonary function and onset of action in subjects with persistent asthma.

Methods: Following a 2- to 4-week run-in period with MF administered via a metered-dose inhaler (MDI) 200 μg (delivered as 2 inhalations of MF-MDI 100 μg) twice daily (BID), subjects (aged ≥12 y) were randomized to MF/F-MDI 200/10 μg BID (delivered as 2 inhalations of MF/F-MDI 100/5 μg) or FP/S administered via a dry powder inhaler (DPI) 250/50 μg (delivered as 1 inhalation) BID for 12 weeks. The primary assessment was change from baseline to week 12 in area under the curve for forced expiratory volume in 1 second measured serially for 0-12 hours postdose (FEV1 AUC0-12 h). Secondary assessments included onset of action (change from baseline in FEV1 at 5 minutes postdose on day 1) and patient-reported outcomes.

Results: 722 subjects were randomized to MF/F-MDI (n = 371) or FP/S-DPI (n = 351). Mean FEV1 AUC0-12 h change from baseline at week 12 for MF/F-MDI and FP/S-DPI was 3.43 and 3.24 L × h, respectively (95% CI, -0.40 to 0.76). MF/F-MDI was associated with a 200-mL mean increase from baseline in FEV1 at 5 minutes postdose on day 1, which was significantly larger than the 90-mL increase for FP/S-DPI (P < 0.001). The overall incidence of adverse events during the 12-week treatment period that were considered related to study therapy was similar in both groups (MF/F-MDI, 7.8% [n = 29]; FP/S-DPI, 8.3% [n = 29]).

Conclusions: The results of this 12-week study indicated that MF/F improves pulmonary function and asthma control similar to FP/S with a superior onset of action compared with FP/S. Both drugs were safe, improved asthma control, and demonstrated similar results for other secondary study endpoints.

Trial registration: ClinicalTrials.gov: NCT00424008.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study Design*. BID = twice daily; DPI = dry powder inhaler; FP/S = fluticasone propionate/salmeterol; MDI = metered-dose inhaler; MF = mometasone furoate; MF/F = mometasone furoate/formoterol. *Doses were delivered via 2 actuations of an MDI (MF 100 μg or MF/F 100/5 μg) or 1 actuation of a DPI (FP/S 250/50 μg) BID. †In the MF/F-MDI 200/10 μg BID treatment group, 42% of subjects discontinued. ‡In the FP/S-DPI 250/50 μg BID treatment group, 41% of subjects discontinued.
Figure 2
Figure 2
Serial FEV1 (0-12 h) and Standardized FEV1 AUC0-12 h at Week 12 (LOCF). AUC = area under the curve; BID = twice daily; DPI = dry powder inhaler; FEV1 = forced expiratory volume in 1 second; FP/S = fluticasone propionate/salmeterol; LOCF = last observation carried forward; MDI = metered-dose inhaler; MF/F = mometasone furoate/formoterol.
Figure 3
Figure 3
Onset of Action: Serial FEV1 (0-1 h) at Day 1. BID = twice daily; DPI = dry powder inhaler; FEV1 = forced expiratory volume in 1 second; FP/S = fluticasone propionate/salmeterol; MDI = metered-dose inhaler; MF/F = mometasone furoate/formoterol. *P < 0.001.
Figure 4
Figure 4
Mean Total ACQ* (top) and AQLQ(S)† (bottom) Scores. ACQ = Asthma Control Questionnaire; AQLQ(S) = Asthma Quality of Life Questionnaire With Standardized. Activities; BID = twice daily; DPI = dry powder inhaler; FP/S = fluticasone propionate/salmeterol; LOCF = last observation carried forward; MDI = metered-dose inhaler; MF/F = mometasone furoate/formoterol; MID = minimally important difference. *ACQ score based on a 7-point scale that ranged from 0 (best asthma control) to 6 (worst asthma control). †AQLQ(S) score based on a 7-point scale that ranged from 1 (worst quality of life) to 7 (best quality of life).
Figure 5
Figure 5
Proportion of Symptom-Free Days and Nights. BID = twice daily; DPI = dry powder inhaler; FP/S = fluticasone propionate/salmeterol; LOCF = last observation carried forward; MDI = metered-dose inhaler; MF/F = mometasone furoate/formoterol.
See this image and copyright information in PMC

References

    1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. http://www.ginasthma.org/guidelines-gina-report-global-strategy-for-asth... Accessed November 15, 2011.
    1. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm Accessed December 14, 2010.
    1. Meltzer EO, Kuna P, Nolte H, S Nayak A, Laforce C, on Behalf of the P04073 Study Investigators. Mometasone Furoate/Formoterol Reduces Asthma Deteriorations and Improves Lung Function. Eur Rispirol J. 2011. in press http://erj.ersjournals.com/content/early/2011/08/04/09031936.00020310.long. Accessed Sep 7, 2011. - PubMed
    1. Nathan RA, Nolte H, Pearlman DS. Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids. Allergy Asthma Proc. 2010;31(4):269–279. doi: 10.2500/aap.2010.31.3364. - DOI - PubMed
    1. Weinstein SF, Corren J, Murphy K, Nolte H, White M. Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg and 400/10 microg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids. Allergy Asthma Proc. 2010;31(4):280–289. doi: 10.2500/aap.2010.31.3381. - DOI - PubMed

Associated data